Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback